Technology | Radial Access | February 17, 2017

Medtronic Expands Coronary Portfolio With New Tools for Transradial Approach

Full line of transradial products and comprehensive training programs includes diagnostic catheters, compression devices

February 17, 2017 — Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several transradial-specific products. Additional products include the DxTerity TRA, InTRAkit access kit and TRAcelet compression device, all of which received U.S. Food and Drug Administration (FDA) clearance and CE (Conformité Européenne) Mark for use in diagnostic cardiac catheterization procedures and percutaneous coronary intervention (PCI). 

The DxTerity and DxTerity TRA Diagnostic Catheters are used to determine whether or not revascularization is necessary in patients with coronary artery disease; the DxTerity TRA Diagnostic Catheters are specifically designed for transradial access and allow for engagement of both coronary arteries without catheter exchange. The InTRAkit access kit enhances the transradial experience by providing several component pieces — ergonomic needles that offer excellent flashback visualization, atraumatic mini-guidewires, as well as tapered introducer sheaths that provide kink resistance and enhanced lubricity for easy insertion. The TRAcelet compression device simplifies pressure reduction post-transradial catheterization by facilitating access site patent hemostasis (i.e., stops bleeding while maintaining radial artery patency).

“The global approval of the DxTerity Diagnostic Catheters, as well as the introduction of the new Medtronic suite of transradial products represents a significant step forward for patients requiring PCI procedures,“ said Sunil Rao, M.D., interventional cardiologist and associate professor of medicine at Duke University, in Durham, N.C.  “It’s increasingly important to have a full suite of products accompanied by robust training to increase physician utilization, improve patient comfort and enable same-day discharge.”

In the United States, Medtronic also launched the Transradial Arc Curriculum, a fully-customizable education and training solution for physicians, staff and administrators to ensure successful adoption of the transradial approach from access to patent hemostasis. The curriculum aims to provide robust clinical training and enhance patient care pathways through a hospital-specific approach to help institutions optimize the delivery of transradial care.

A meta-analysis of randomized studies of the transradial approach generally have found that procedures via the transradial approach (through a patient’s wrist) have been associated with cost savings, reduced mortality and improved safety, with reductions in major bleeding and vascular complications.

The DxTerity and DxTerity TRA Diagnostic Catheters, TRAcelet compression device and the InTRAkit Access Kit are commercially available in the United Staets, as well as throughout Europe. The Transradial Arc Curriculum is only available in the U.S.

For more information: www.medtronic.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init